EVALUATION OF SERUM γ-GLUTAMYL TRANSFERASE AND ITS ASSOCIATION WITH HIGH SENSITIVITY C-REACTIVE PROTEIN AND INSULIN LEVELS IN THE PATIENTS WITH METABOLIC SYNDROME
DOI:
https://doi.org/10.11603/ijmmr.2413-6077.2019.1.9693Keywords:
metabolic syndrome, gamma-glutamyl transferase, high sensitivity C-reactive protein, HOMA-IRAbstract
Background. Metabolic syndrome (MS), a collection of cardiovascular risk factors, is a major worldwide public health problem. The gathered data prove that serum gamma-glutamyl transferase (γGT) activity is a true marker of atherosclerotic cardiovascular disease (CVD) and is of a prognostic importance as well as the high-sensitivity C-reactive protein (hs-CRP).
Objectives. In the study, we sought to evaluate serum γGT activity, hs-CRP and insulin resistance in patients with MS.
Methods. The study involved 50 persons with metabolic syndrome and 50 healthy age and sex matched controls. Fasting serum samples of all participants were investigated for γGT, hs-CRP, insulin, blood glucose, lipid profile and liver function tests. Anthropometric measurements and BMI were also calculated
Results. In that case 50% showed significantly high γGT compared to the controls, 30% proved increased hs-CRP levels above >0.5 mmol/L, whereas 94% of the controls were within the reference range. 74% of cases revealed the presence of insulin resistance while 32% of the controls showed insulin resistance. High γGT levels were also observed in that case with deranged lipids levels and high BMI.
Conclusions. The study suggests that the patients with MS have a higher serum γGT activity. This study also proves that hs-CRP and HOMA-IR, which are independent risk factors of CVD, are also associated with MS. The correlation between γGT and the components of MS are also found significant compared to hs-CRP. Thus, γGT can be considered as an inexpensive and authentic predictor of MS, which can be a manifestation of CVD in near future.
References
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; International atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120:1640-5. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.192644
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113-32. DOI: https://doi.org/10.1016/j.jacc.2010.05.034
Nemesánszky E, Lott JA. Gamma-glutamyltransferase and its isoenzymes: Progress and problems. Clin Chem. 1985;31:797-803. DOI: https://doi.org/10.1093/clinchem/31.6.797
https://www.ncbi.nlm.nih.gov/pubmed/2859933
André P, Balkau B, Vol S, Charles MA, Eschwège E, DESIR Study Group, et al. Gamma-glutamyltransferase activity and development of the meta_bolic syndrome (International diabetes federation definition) in middle-aged men and women: Data from the epidemiological study on the insulin resistance syndrome (DESIR) cohort. Diabetes Care. 2007;30:2355-61. DOI: https://doi.org/10.2337/dc07-0440
Targher G. Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - A narrative review. Clin Chem Lab Med. 2010;48:147-57. DOI: https://doi.org/10.1515/CCLM.2010.031
Turgut O, Tandogan I. Gamma-glutamyltransferase to determine cardiovascular risk: Shifting the paradigm forward. J Atheroscler Thromb. 2011;18:177-81. DOI: https://doi.org/10.5551/jat.6189
Cho NH, Jang HC, Choi SH, Kim HR, Lee HK, Chan JC, et al. Abnormal liver function test predicts type 2 diabetes: A community-based prospective study. Diabetes Care. 2007;30:2566-8. DOI: https://doi.org/10.2337/dc07-0106
Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost HG, Boeing H, et al. Liver enzymes and incident diabetes: Findings from the European prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes Care. 2008;31:1138-43. DOI: https://doi.org/10.2337/dc07-2159
Sato KK, Hayashi T, Nakamura Y, Harita N, Yoneda T, Endo G, et al. Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: The Kansai healthcare study. Diabetes Care. 2008;31:1230-6. DOI: https://doi.org/10.2337/dc07-2184
Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-30. DOI: https://doi.org/10.1172/JCI200319451
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American heart association/National heart, lung, and blood institute scientific statement: Executive summary. Crit Pathw Cardiol. 2005;4:198-203 DOI: https://doi.org/10.1097/00132577-200512000-00018
Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl. 2003;134:10-7.
https://www.ncbi.nlm.nih.gov/pubmed/12793593
González AS, Guerrero DB, Soto MB, Díaz SP, Martinez-Olmos M, Vidal O, et al. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr. 2006;60:802-9. DOI: https://doi.org/10.1038/sj.ejcn.1602384
Wei D, Chen T, Gao Y, Tian H. Serum gamma-glutamyltransferase and ferritin are related to insulin resistance: A Population-based study. Clin Lab. 2015;61:1157-61. DOI: https://doi.org/10.7754/Clin.Lab.2015.150227
Emdin M, Passino C, Michelassi C, Donato L, Pompella A, Paolicchi A, et al. Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. Int J Cardiol. 2009;136:80-5. DOI: https://doi.org/10.1016/j.ijcard.2008.04.030
Du G, Song Z, Zhang Q. Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: A meta-analysis of prospective cohort studies. Prev Med. 2013;57:31-7. DOI: https://doi.org/10.1016/j.ypmed.2013.03.011
Kunutsor SK, Apekey TA, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: A systematic review and dose-response meta-analysis. Int J Clin Pract. 2015;69:136-44. DOI: https://doi.org/10.1111/ijcp.12507
Relationship between serum gamma-glutamyltransferase activity and cardiometabolic risk factors in metabolic syndrome. J Family Med Prim Care. 2018;7(2):430-434. DOI: https://doi.org/10.4103/jfmpc.jfmpc_194_17
Liu CF, Gu YT, Wang HY, Fang NY. Gamma-glutamyltransferase level and risk of hypertension: A systematic review and meta-analysis. PLoS One. 2012;7:e48878 DOI: https://doi.org/10.1371/journal.pone.0048878
Stranges S, Trevisan M, Dorn JM, Dmochowski J, Donahue RP. Body fat distribution, liver enzymes, and risk of hypertension: Evidence from the western New York study. Hypertension. 2005;46:1186-93. DOI: https://doi.org/10.1161/01.HYP.0000185688.81320.4d
Ortega E, Koska J, Salbe AD, Tataranni PA, Bunt JC. Related articles, links serum gamma-glutamyl transpeptidase is a determinant of insulin resistance independently of adiposity in Pima Indian children. J Clin Endocrinol Metab 2006;91:1419-22. DOI: https://doi.org/10.1210/jc.2005-1783
Aksakal E, Tanboga IH, Kurt M, Kaygın MA, Kaya A, Isik T, et al. The relation of serum gamma-glutamyl transferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis 2012;221:596-601 DOI: https://doi.org/10.1016/j.atherosclerosis.2012.01.044
Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825. DOI: https://doi.org/10.1161/01.CIR.0000132467.45278.59
Lee DH, Jacobs DR Jr. Association between serum gammaglutamyltransferase and C-reactive protein. Atherosclerosis 2005; 178: 327-330. DOI: https://doi.org/10.1016/j.atherosclerosis.2004.08.027
Downloads
Published
How to Cite
Issue
Section
License
Authors who sent their manuscript to International Journal of Medicine and Medical Research agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC-BY-NC that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
